Adult Ewing Sarcoma: Survival and Local Control Outcomes in 102 Patients with Localized Disease

Table 2

Chemotherapy regimens (𝑛=102).

Chemotherapy	Group A (𝑛=50)	Group B (𝑛=52)
VDC/IE	5	43
VACD	9
VDC	8
VAC	3
MAP	3
MAP with RT followed by VDD alternating with VDC	5
MAP, IE		3
Unknown regimen	4	2
VAC alternating with VDD	1
VC	2
VDC, 5FU	1
VDCD	1
IE	1
DI		1
CCT		1
MDCI		1
DDI		1
No chemotherapy administered	6
No chemotherapy information	1

VDC/IE: vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide; VACD: vincristine, actinomycin D, cyclophosphamide, doxorubicin; VDC: vincristine, doxorubicin, cyclophosphamide; VAC: vincristine, actinomycin D, cyclophosphamide; MAP: mitomycin, Adriamycin, cisplatin; VDD: vincristine, doxorubicin, dacarbazine; VDCD: vincristine, doxorubicin, cyclophosphamide, dacarbazine; DI: doxorubicin, ifosfamide; CCT: cyclophosphamide, carboplatin, thiotepa; MDCI: mitomycin, doxorubicin, cisplatin, ifosfamide; DDI: doxorubicin, dacarbazine, ifosfamide.